Johnson & Johnson Stock

Equities

JNJ

US4781601046

Pharmaceuticals

Real-time Estimate Cboe BZX 03:29:46 2024-04-19 pm EDT 5-day change 1st Jan Change
147.6 USD +1.28% Intraday chart for Johnson & Johnson -0.08% -5.96%
Sales 2024 * 88.39B Sales 2025 * 90.82B Capitalization 351B
Net income 2024 * 22.31B Net income 2025 * 23B EV / Sales 2024 * 3.89 x
Net cash position 2024 * 7B Net cash position 2025 * 21.07B EV / Sales 2025 * 3.63 x
P/E ratio 2024 *
16.7 x
P/E ratio 2025 *
15.7 x
Employees 131,900
Yield 2024 *
3.31%
Yield 2025 *
3.46%
Free-Float 77.1%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.62%
1 week-0.44%
Current month-7.16%
1 month-5.98%
3 months-9.16%
6 months-3.58%
Current year-6.30%
More quotes
1 week
143.13
Extreme 143.13
149.49
1 month
143.13
Extreme 143.13
159.14
Current year
143.13
Extreme 143.13
163.58
1 year
143.13
Extreme 143.13
175.97
3 years
143.13
Extreme 143.13
186.69
5 years
109.16
Extreme 109.16
186.69
10 years
81.79
Extreme 81.79
186.69
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 88-12-31
Director of Finance/CFO 57 97-12-31
Chief Tech/Sci/R&D Officer 58 19-11-04
Members of the board TitleAgeSince
Director/Board Member 70 19-04-24
Director/Board Member 72 14-06-18
Director/Board Member 70 09-10-21
More insiders
Date Price Change Volume
24-04-19 147.4 +1.13% 5 039 855
24-04-18 145.7 +0.67% 9,887,704
24-04-17 144.8 +0.22% 9,378,059
24-04-16 144.4 -2.13% 12,774,859
24-04-15 147.6 +0.05% 8,502,266

Delayed Quote Nyse, April 19, 2024 at 12:01 pm EDT

More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
145.7 USD
Average target price
172.5 USD
Spread / Average Target
+18.38%
Consensus